Patrick BERGER

Professeur d'université - Praticien hospitalier. Directeur équipe 2 / Responsable de l'équipe 2

Parcours professionnel

Depuis 2025 : Chef de l’unité d’hospitalisation pour l’asthme, Centre hospitalier universitaire de Bordeaux (CHU)
Depuis 2024 : Chef du service d’explorations fonctionnelles respiratoires, Centre hospitalier universitaire de Bordeaux (CHU)
Depuis 2022 : Directeur du Centre de recherche cardio-thoracique de Bordeaux (CRCTB, INSERM U1045), Université de Bordeaux
Depuis 2011 : Directeur de l’équipe « Remodelage bronchique » (CRCTB, INSERM U1045), Université de Bordeaux
Depuis 2008 : Professeur de physiologie (Université de Bordeaux), praticien hospitalier pneumologue (CHU)

Financements

ANR international PRC (2024-2028)
Financement non fléchée d’AstraZeneca (2021-2023)
Financement AST Prematuration (2021-2024)
Équipe FRM (2017-2020)

Brevets

1. Berger P, Dupin I, Girodet PO.
Brevet déposé le 28 Janvier 2015 sous le numéro de série EP N°15152886.6 auprès de l’Office Européen des Brevets : New compositions and methods of treating and/or preventing Chronic Obstructive Pulmonary Disease.
PCT déposé le 28 Janvier 2016 PCT/EP2016/051771 pour les pays USA, Canada, Australie, BRIC, Israel, Japon, Eurasie.
Brevet délivré le 9/10/2019 sous le numéro de série EP N°3050574 : Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease.
Publication mondiale effective le 4 Août 2016 sous le N° WO/2016/120369A1.
Licence signée le 26 Juillet 2025 avec 4 Living Biotech

2. Dournes G, Baldacci F, Laurent F, Berger P.
Brevet Français déposé le 27 Mai 2016 sous le numéro de série 22605-FR auprès de l’Office Français des Brevets : Procédé de caractérisation géométrique des voies aériennes d’un poumon par IRM.
Extension européenne déposée le 29 Mai 2017 à l’office européen des brevets : MRI Method for the geometrical characterization of pulmonary airways (N° 17726309.2; N°16/304,574), délivré le 5 Juillet 2019. Extension américaine déposée le 29 Mai 2017 et délivrée aux USA sous le N° US 11,361,429 B2 le 14 Juin 2022. Publication mondiale effective au 30 Novembre 2017 sous le N° WO/2017/203064A1.

3. Dournes G, Benlala I, Laurent F, Berger P.
Brevet Français déposé le 31 Juillet 2019 sous le numéro de série 1908734-FR auprès de l’Office Français des Brevets : Procédé de génération d’un biomarqueur système.
PCT déposé le 3 Juin 2020 PCT/EP2020/065380 auprès de l’office européen des brevets. Method for generating a biomarker system. Brevet délivré le 4 Février 2021 sous le N° 3099621.
Publication mondiale effective au 4 Février 2021 sous le N° WO/2021/018439A1

4. Berger P, Dupin I, Prevel R, James C, Girodet PO, Bismuth K, Rattenbach R.
Brevet déposé le 7 Mai 2020 sous le numéro de série EP N°20173595.8 auprès de l’Office Européen des Brevets (en examen) : New compositions and methods of treating COVID-19 Disease.
Contrat de licence signé par 4-Living Biotech le 16 Juillet 2021.
Publication mondiale effective au 11 Novembre 2021 sous le N° WO/2021/224356.

5. Rattenbach R, Breton J, Chéron V, Prevel R, Berger P.
CXCR4 inhibitor compound in the treatment and/or the prevention of severe ARDS
Licence signée le 26 Juillet 2025 avec 4 Living Biotech
Publication mondiale effective le 2 octobre 2025 sous le N° WO/2025/202445.

Membres

Patrick BERGER

Parcours professionnel

Financements

Brevets

Publications 295

Quantitative CT Evaluation of Bronchiectasis Improvement in Cystic Fibrosis after CFTR-Modulator Therapy

2024 imaging criteria for allergic bronchopulmonary aspergillosis: which diagnostic cut-offs? Are chest radiograph and CT comparable?

Bronchial wall T2w MRI signal as a new imaging biomarker of severe asthma

Celastrol has beneficial effects on pulmonary hypertension associated with bronchopulmonary dysplasia: Preclinical study outcomes

Artificial intelligence-driven volumetric CT outcome score in cystic fibrosis: longitudinal and multicenter validation with/without modulators treatment

Long-term effectiveness and safety of dupilumab in severe asthma: A 5-year real-world multicenter study

Validity and reliability of anharmonic morphological ventilometry for the characterisation of human breathing

Tunable 3D Alveolosphere Model from Human Alveolar Cells: A Breakthrough Tool to Explore Emphysema Pathophysiology

3D SEMANTIC SEGMENTATION OF AIRWAY ABNORMALITIES ON UTE-MRI WITH REINFORCEMENT LEARNING ON DEEP SUPERVISION

What is the true target population for biologics in real-life COPD or asthma-COPD overlap patients?

A novelin vitrotubular model to recapitulate features of distal airways: the bronchioid

Imagerie tomodensitométrique de la bronchopneumopathie chronique obstructive : quels aspects et quel rôle ?

Airway bacterial colonization is associated with bronchial remodeling in severe preschool wheezers

COBRAPed cohort: Do sensitization patterns differentiate children with severe asthma from those with a milder disease?

Clinical and bronchial parameters associated with the exacerbation frequency of severe preschool wheezers

Commentary: Effect of curcumin nanoparticles on proliferation and migration of mouse airway smooth muscle cells and airway inflammatory infiltration

Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy

Guselkumab Decreases Key Cellular Inflammatory Processes Across Ileum and Colon Tissue in Crohn’s Disease

Histologic and Combined Histologic and Endoscopic Outcomes After Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Week 44 Results From the Phase 3 QUASAR Maintenance Study

IDENTIFICATION AND RANKING OF GENE MODULE ASSOCIATION WITH HISTOLOGIC FEATURES IN ULCERATIVE COLITIS

GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY

DEVELOPMENT OF A CROHN’S DISEASE MOLECULAR ACTIVITY SCORE TO IDENTIFY REGION-SPECIFIC CHRONICALLY INFLAMED AND NONINFLAMED PROCESSES

HIGH PERFORMANCE ESTIMATION OF GEBOES SCORE IN ULCERATIVE COLITIS USING MULTI-INSTANCE LEARNING AND FOUNDATIONAL MODELS

GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

A novel in vitro tubular model to recapitulate features of distal airways: The bronchioid

Deep Learning Models Capture Histological Disease Activity in Crohn’s Disease and Ulcerative Colitis with High Fidelity

Development and external validation of a prediction model for the transition from mild to moderate or severe form of COVID-19

Generating High-Resolution Synthetic CT from Lung MRI with Ultrashort Echo Times: Initial Evaluation in Cystic Fibrosis

Non‐Contrast‐Enhanced Functional Lung MRI to Evaluate Treatment Response of Allergic Bronchopulmonary Aspergillosis in Patients With Cystic Fibrosis: A Pilot Study

Lung Mycobiota α-Diversity Is Linked to Severity in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Bridging gut microbiota composition with extended-spectrum beta-lactamase Enterobacteriales faecal carriage in critically ill patients (microbe cohort study)

Adherence, reliability, and variability of home spirometry telemonitoring in cystic fibrosis

Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps

Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting

Cellular interplay in skeletal muscle regeneration and wasting: insights from animal models

Non-contrast-Enhanced Functional Lung MRI to evaluate treatment response of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: a pilot study

CXCR4 blockade alleviates pulmonary and cardiac outcomes in young COPD

Impact of Guselkumab Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the Phase 3 QUASAR Induction Study

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

Lung microbiota compositions differ between influenza, COVID-19 and bacteria-related acute respiratory distress syndrome

Biopsy and blood-based molecular biomarker of inflammation in IBD

Using an electronic diary and wristband accelerometer to detect exacerbations and activity levels in COPD: a feasibility study

USTEKINUMAB MODULATES IL-12 AND IL-23-RELATED CELL TYPE-SPECIFIC INFLAMMATORY TRANSCRIPTIONAL STATES IN ULCERATIVE COLITIS INDUCTION THERAPY

Pathophysiology of severe asthma : What are the molecular targets for biotherapies?

Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD

Gut bacteriobiota and mycobiota are both associated with Day-28 mortality among critically ill patients

Laparoscopic fundoplication for para-oesophageal hernia repair improves respiratory function in patients with dyspnoea: a prospective cohort study

Inflammation and Oxidative Stress Induce NGF Secretion by Pulmonary Arterial Cells through a TGF-β1-Dependent Mechanism

Piezo1 Channel Activation Reverses Pulmonary Artery Vasoconstriction in an Early Rat Model of Pulmonary Hypertension: The Role of Ca2+ Influx and Akt-eNOS Pathway

Bronchial epithelia from adults and children: SARS-CoV-2 spread via syncytia formation and type III interferon infectivity restriction

Cell Confluence Modulates TRPV4 Channel Activity in Response to Hypoxia

Rhinovirus infection of bronchial epithelium induces specific bronchial smooth muscle cell migration of severe asthmatic patients

Principaux messages de la première Biennale BPCO 2021 de la SPLF. Mieux comprendre pour innover

NiONP-Induced Oxidative Stress and Mitochondrial Impairment in an In Vitro Pulmonary Vascular Cell Model Mimicking Endothelial Dysfunction

Asthmatic bronchial smooth muscle increases rhinovirus replication within the bronchial epithelium

Artificial intelligence in computed tomography for quantifying lung changes in the era of CFTR modulators

Muscarinic receptor M3 activation promotes fibrocytes contraction

Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging

Increased airway smooth muscle cells in asthma: mechanisms and therapeutic prospects

Short-range interactions between fibrocytes and CD8+ T cells in COPD bronchial inflammatory response

Dupilumab long-term efficacy in patients with asthma with or without comorbid chronic rhinosinusitis/nasal polyposis enrolled in LIBERTY ASTHMA TRAVERSE from phase 2b study

Dupilumab long-term efficacy in patients with asthma with or without comorbid chronic rhinosinusitis/nasal polyposis enrolled in LIBERTY ASTHMA TRAVERSE from phase 2b study

Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing

Is CCL18 a potential biomarker of type-2 asthma endotypes?

Circulating fibrocytes as a new tool to predict lung cancer progression after surgery?

Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling.

Mitochondria are involved in bronchial smooth muscle remodeling in severe preschool wheezers.

Individual trajectory-based care for COPD: getting closer, but not there yet

Contractile cell apoptosis regulates airway smooth muscle remodeling in asthma

Analysis of spontaneous breathing can predict abnormal lung function in asthma

Human rhinovirus induce specific bronchial smooth muscle migration toward bronchial epithelium in severe asthma through the CXCL10/CXCR3 axis

Mitochondria are involved in bronchial smooth muscle remodeling in severe preschool wheezers

Bronchial smooth muscle of severe asthmatic patients decreases rhinovirus replication within the epithelium through a CCL-20/PKR/eIF2-a dependent pathway

Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodeling

Short-range interactions between fibrocytes and CD8⁺ T cells in COPD bronchial inflammatory response